AstraZeneca PLC (LON:AZN – Get Free Report) insider Michel Demare acquired 2,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was purchased at an average price of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57).
AstraZeneca Trading Up 0.7 %
Shares of LON:AZN opened at £120.16 ($158.73) on Tuesday. AstraZeneca PLC has a twelve month low of GBX 9,461 ($124.98) and a twelve month high of £133.88 ($176.86). The firm has a market cap of £186.25 billion, a P/E ratio of 3,851.28, a P/E/G ratio of 0.93 and a beta of 0.17. The company has a 50 day moving average of £125.81 and a 200-day moving average of £119.05. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.
AstraZeneca Cuts Dividend
The company also recently declared a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were issued a dividend of GBX 77.60 ($1.03) per share. The ex-dividend date of this dividend was Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s dividend payout ratio is currently 7,500.00%.
Analyst Ratings Changes
Read Our Latest Stock Report on AZN
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Use the MarketBeat Dividend Calculator
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What is the S&P/TSX Index?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.